Investor's Business Daily • 15 hours ago
When Peter Gassner started Veeva in 2007, he had one primary goal -- replace biopharma companies' legacy systems with cloud-based software.
The Wall Street Journal • 15 hours ago
Apple Tree Partners is bankrolling a startup that could make treating recurring ear infections easier for children and less nerve-wracking for parents.
Forbes • 16 hours ago
Looking at the earnings posted by Merck & Co. (MRK), I could not help but compare and contrast them with what Sanofi (SNY) said this morning. Like Sanofi had with Lantus, Merck has a mega-blockbuster with Januvia. Just as Lantus was getting long in the tooth and facing patent expiration
Market Realist • 22 hours ago
With 80% of the total patients on antiretroviral therapy using the company’s HIV drugs in the US, Gilead Sciences (GILD) continues to be a leading player in the HIV segment.
Investopedia • 2 days ago
This will be the final year of Eli Lilly (NYSE: LLY) President and CEO John Lechleiter's tenure. The company has announced that he will vacate both posts on Dec. 31. He will continue to serve as chairman ...
Reuters • 2 days ago
Even though many doctors see need for improvement, surgical robots are poised for big gains in operating rooms around the world. Within five years, one in three U.S. surgeries - more than double current levels - is expected to be performed with robotic systems, with surgeons sitting at computer consoles guiding mechanical arms. Robotic surgery has been long dominated by pioneer Intuitive Surgical Inc, which has more than 3,600 of its da Vinci machines in hospitals worldwide and said last week the number of procedures that used them jumped by 16 percent in the second quarter compared to a year earlier.
Johnson & JohnsonNYSE
After hours: 125.310.08 (0.06%) as of 7:53 PM EDT
|Bid||125.20 x 100|
|Ask||125.33 x 500|
|52wk Range||81.79 - 126.07|
|Day's Range||124.34 - 125.32|
|Avg Vol (3m)||6,990,004|
As of 4:00 PM EDT. Market closed.